Artiva Biotherapeutics (ARTV) Cash from Investing Activities (2023 - 2026)

Artiva Biotherapeutics (ARTV) has reported Cash from Investing Activities for 4 consecutive years, with $15.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 53.61% year-over-year to $15.3 million; the TTM figure through Mar 2026 stood at $68.8 million (up 157.17% YoY), while the FY2025 annual figure was $63.4 million, up 152.64% from the prior year.
• Cash from Investing Activities declined to $15.3 million in Q1 2026 per ARTV's latest filing, from $16.0 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $21.1 million in Q2 2025 and bottomed at -$130.6 million in Q3 2024.
• Historically, Cash from Investing Activities has averaged -$4.1 million across 4 years, with a median of $9.8 million in 2024.
• Annual changes were most pronounced in 2024 — Cash from Investing Activities slumped 26396.55% — and 2025, when it surged 1760.46%.
• Artiva Biotherapeutics' Cash from Investing Activities stood at -$2.7 million in 2023, then surged by 63.79% to -$966000.0 in 2024, then soared by 1760.46% to $16.0 million in 2025, then slipped by 4.51% to $15.3 million in 2026.
• Business Quant data shows ARTV's Cash from Investing Activities at $15.3 million in Q1 2026, $16.0 million in Q4 2025, and $16.3 million in Q3 2025.